BioHarvest Sciences Inc. has announced the successful completion of Stage 1 in its CDMO contract with a Nasdaq-listed pharmaceutical company, marking a significant milestone in the development of a novel plant-based compound. The completion of this stage validates the company's proprietary Botanical Synthesis platform, which effectively isolated and multiplied target plant cells to develop active pharmaceutical compounds. Moving forward to Stage 2, BioHarvest will focus on scaling biomass and refining compound concentration to meet commercial production demands. This progress underscores the platform's versatility and enhances BioHarvest's analytical capabilities for future projects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.